Detalhe da pesquisa
1.
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Am J Hematol
; 94(1): 74-79, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30328139